Magrilan

Fluoxetine, the active ingredient in Magrilan, is a selective serotonin reuptake inhibitor (SSRI) presented as an oral dosage form for oral use. It treats major depressive disorder and related psychiatric conditions in adult patients.

GNH USA supplies Magrilan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Magrilan belongs to the SSRI class and is prescribed for several mood‑related disorders. - Major depressive disorder: reduces depressive symptoms and improves overall mood. - Obsessive‑compulsive disorder: lessens intrusive thoughts and compulsive behaviours. - Panic disorder: decreases frequency and intensity of panic attacks. - Bulimia nervosa: helps control binge‑eating and purging cycles. - Premenstrual dysphoric disorder: alleviates severe premenstrual mood swings.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or throbbing pain. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation. - Sexual dysfunction: decreased libido or delayed orgasm. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Suicidal thoughts: emergence of suicidal ideation, especially early in treatment. - Severe allergic reaction: rash, swelling, or anaphylaxis. - QT interval prolongation: potential cardiac arrhythmias. - Hyponatremia: low blood sodium, particularly in elderly patients. - Abnormal bleeding: increased risk when combined with anticoagulants.

Magrilan requires careful clinical monitoring and patient education. - Assess psychiatric history: watch for worsening depression or new suicidal thoughts, especially during the first weeks. - Avoid concurrent MAO inhibitors: maintain a minimum 14‑day washout period. - Use caution in hepatic impairment: liver function may affect drug clearance. - Monitor electrolytes: risk of hyponatremia, particularly in older adults. - Discuss pregnancy and lactation: evaluate risk‑benefit with prescriber. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Magrilan can interact with several medicines that affect serotonin levels or bleeding risk. Major Interactions (Avoid): - MAO inhibitors: risk of serotonin syndrome. - Pimozide or thioridazine: may cause cardiac arrhythmias. - Linezolid: additive serotonergic activity. Moderate Interactions (Monitor Closely): - NSAIDs or anticoagulants: increased bleeding tendency. - Other serotonergic agents (e.g., tramadol, triptans): potential for serotonin syndrome. - Carbamazepine: may reduce fluoxetine plasma concentrations.